Citi Reiterates Buy Rating on PhaseBio (PHAS); Most Undervalued in Coverage
Tweet Send to a Friend
Citi analyst Joel Beatty reiterated a Buy rating and $25.00 price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS), calling it ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
